25th Oct 2013 09:49
Grant of Share Options
Clinigen Group plc ("Clinigen" or the "Company") (AIM: CLIN), announces that, on 23 October 2013, it granted share options over a total of 295,315 ordinary shares of 0.1 pence each ("Ordinary Shares") to the directors listed below, under the Clinigen Group Long Term Incentive Plan. The options are nil cost options which vest on 26 September 2016, subject to the achievement of certain performance criteria.
Director | Number of share options granted on 23 October 2013 | Total number of share options now held |
Peter George | 58,386 | 883,942 |
Robin Sibson | 30,540 | 30,540 |
Shaun Chilton | 206,389 | 619,167 |
Contact Details
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Peter George, Group Chief Executive Officer | |
Robin Sibson, Chief Financial Officer | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) | |
James Black/Tom Ballard/Jamie Loughborough (Corporate Broking) | |
|
|
Peel Hunt LLP - Joint Broker | Tel: +44 (0) 20 7418 8900 |
Jock Maxwell Macdonald (Corporate Sales & Syndication) James Steel / Dr Vijay Barathan |
|
College Hill (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Stefanie Bacher/Jen Lewis | Email: clinigen@collegehill.com |
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. Listed at The London Stock Exchange AIM, the Group has three operating businesses; Specialty Pharmaceuticals (Clinigen SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. Clinigen CTS sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. Clinigen GAP specializes in the consultancy, development, management and implementation of programs, providing global access for patients and their clinicians to drugs not available in their markets. For more information, please visit www.clinigengroup.com.
Related Shares:
CLIN.L